2021

An internationally-known mesothelioma specialist says 2021 has been one of the best years yet for malignant mesothelioma research, giving patients and their families more reason than ever to be hopeful.  Hedy Lee Kindler, MD, is Director of the University of Chicago Medical Center’s Mesothelioma Program. In a commentary in JCO Oncology Practice, Dr. Kindler says the outlook for mesothelioma sufferers this year is “far brighter than it has been for a very long time.” Dr. Kindler points to several recent advances in malignant mesothelioma research and treatment as reasons for optimism. The FDA approved the second systemic therapy for mesothelioma in late 2020. This year saw five positive mesothelioma clinical trials.  Kindler says these advances suggest that the future may…